**Table S2.** Baseline patient characteristics of conversion cases.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Patient characteristics at baseline | | | | | | | | | | | |
| Case | | Drugs | Age | Sex | Etiology | Treatment  line | AFP  (ng/mL) | Child-Pugh  score | mALBI  score | Tumor  number | Maximum  tumor size (mm) | BCLC  stage |
| 1 | | LEN | 74 | M | NASH | First | 13 | 5 | 2a | 5 | 23 | B |
| 2 | | LEN | 72 | M | Alcohol | First | 6 | 5 | 1 | 4 | 51 | B |
| 3 | | LEN | 69 | M | Alcohol | First | 1,637 | 5 | 2a | 3 | 73 | B |
| 4 | | LEN | 71 | F | NASH | First | 4 | 5 | 2a | 10 | 61 | B |
| 5 | | LEN | 79 | M | HCV | First | 10,950 | 6 | 1 | 2 | 42 | B |
| 6 | | LEN | 71 | F | NASH | First | 11 | 6 | 2b | 1 | 64 | B |
| 7 | | A/B | 80 | M | HCV | First | 162 | 5 | 2a | 1 | 81 | C |
| 8 | | A/B | 76 | F | HCV | First | 832 | 5 | 2a | 5 | 33 | B |
| 9 | | A/B | 60 | M | NASH | Third | 3,024 | 6 | 2a | 3 | 32 | B |
| 10 | | A/B | 78 | M | HCV | First | 5 | 5 | 2a | 6 | 28 | B |
| 11 | | A/B | 78 | F | HCV | First | 268 | 5 | 1 | 4 | 21 | B |
| 12 | | A/B | 79 | M | Alcohol | First | 3 | 5 | 1 | 5 | 68 | B |
| Median | | - | 75 | - | - | - | 88 | 5 | - | 4 | 47 | - |

AFP, alpha-fetoprotein; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer**;** LEN, Lenvatinib; HBV, hepatitis B virus; HCV, hepatitis C virus